United Nations Children’s Fund (UNICEF), the 
World Health Organization (WHO), the United Na-
tions Development Programme (UNDP), the Global
Fund to Fight AIDS, Tuberculosis and Malaria and 
other appropriate international organizations (such 
as the International Bank for Reconstruction and 
Development), relevant regional multilateral develop-
ment institutions, national, state, and local govern-
ments of foreign countries, appropriate governmental 
and nongovernmental organizations, and relevant 
Executive branch agencies. 
‘‘(d) ACTIVITIES SUPPORTED.—Assistance provided 
under subsection (c) shall, to the maximum extent prac-
ticable, be used to carry out the following activities: 
‘‘(1) PREVENTION.—Prevention of HIV/AIDS 
through activities including—
‘‘(A) education, voluntary testing, and 
counseling (including the incorporation of con-
fidentiality protections with respect to such 
testing and counseling), including integration of 
such programs into health programs and the in-
clusion in counseling programs of information 
on methods of preventing transmission of the 
HIV infection, including delaying sexual debut, 
abstinence, 
reduction 
of 
casual 
sexual
partnering, and, where appropriate, the use of 
condoms; 
‘‘(B) assistance for the purpose of pre-
venting mother-to-child transmission of the 
HIV infection, including medications to prevent 
such transmission and access to infant formula 
and other alternatives for infant feeding; 
‘‘(C) assistance to ensure a safe blood sup-
ply, to provide—
‘‘(i) post-exposure prophylaxis to vic-
tims of rape and sexual assault and in 
cases of occupational exposure of health 
care workers; and 
‘‘(ii) necessary commodities, including 
test kits, pharmaceuticals, and condoms; 
‘‘(D) assistance through nongovernmental 
organizations, including faith-based organiza-
tions, particularly those organizations that uti-
lize both professionals and volunteers with ap-
propriate skills and experience, to establish and 
implement culturally appropriate HIV/AIDS 
education and prevention programs; 
‘‘(E) research on microbicides which pre-
vent the spread of HIV/AIDS; and
‘‘(F) bulk purchases of available prevention 
technologies for women and for appropriate pro-
gram support for the introduction and distribu-
tion of these technologies, as well as education 
and training on the use of the technologies. 
‘‘(2) TREATMENT.—The treatment and care of 
individuals with HIV/AIDS, including—
‘‘(A) assistance to establish and implement 
programs to strengthen and broaden indigenous 
health care delivery systems and the capacity of 
such systems to deliver HIV/AIDS pharma-
ceuticals and otherwise provide for the treat-
ment of individuals with HIV/AIDS, including 
clinical training for indigenous organizations 
and health care providers; 
‘‘(B) assistance to strengthen and expand 
hospice and palliative care programs to assist 
patients debilitated by HIV/AIDS, their fami-
lies, and the primary caregivers of such pa-
tients, including programs that utilize faith-
based and community-based organizations; and 
‘‘(C) assistance for the purpose of the care 
and treatment of individuals with HIV/AIDS 
through the provision of pharmaceuticals, in-
cluding antiretrovirals and other pharma-
ceuticals and therapies for the treatment of op-
portunistic infections, nutritional support, and 
other treatment modalities. 
‘‘(3) MONITORING.—The monitoring of pro-
grams, projects, and activities carried out pursuant 
to paragraphs (1) and (2), including—
‘‘(A) monitoring to ensure that adequate 
controls are established and implemented to 
provide HIV/AIDS pharmaceuticals and other 
appropriate medicines to poor individuals with 
HIV/AIDS; and 
‘‘(B) appropriate evaluation and surveil-
lance activities. 
‘‘(4) PHARMACEUTICALS.—
‘‘(A) PROCUREMENT.—The procurement of 
HIV/AIDS pharmaceuticals, antiviral therapies, 
and other appropriate medicines, including 
medicines to treat opportunistic infections. 
‘‘(B) MECHANISMS FOR QUALITY CONTROL 
AND
SUSTAINABLE
SUPPLY.—Mechanisms to 
ensure that such HIV/AIDS pharmaceuticals, 
antiretroviral therapies, and other appropriate 
medicines are quality-controlled and sustainably 
supplied.
‘‘(C) DISTRIBUTION.—The distribution of 
such 
HIV/AIDS 
pharmaceuticals, 
antiviral 
therapies, and other appropriate medicines 
(including medicines to treat opportunistic in-
fections) to qualified national, regional, or local 
organizations for the treatment of individuals 
with HIV/AIDS in accordance with appropriate 
HIV/AIDS testing and monitoring requirements 
and treatment protocols and for the prevention 
of mother-to-child transmission of the HIV in-
fection. 
‘‘(5) RELATED ACTIVITIES.—The conduct of re-
lated activities, including—
‘‘(A) the care and support of children who 
are orphaned by the HIV/AIDS pandemic, in-
cluding services designed to care for orphaned 
children in a family environment which rely on 
extended family members; 
‘‘(B) improved infrastructure and institu-
tional capacity to develop and manage edu-
cation, prevention, and treatment programs, in-
cluding training and the resources to collect 
and maintain accurate HIV surveillance data to 
target programs and measure the effectiveness 
of interventions; and
‘‘(C) vaccine research and development 
partnership programs with specific plans of ac-
tion to develop a safe, effective, accessible, pre-
ventive HIV vaccine for use throughout the 
world. 
‘‘(e) ANNUAL REPORT.—
‘‘(1) IN GENERAL.—Not later than January 31 
of each year, the President shall submit to the Com-
mittee on Foreign Relations of the Senate and the 
Committee on International Relations of the House 
of Representatives a report on the implementation of 
this section for the prior fiscal year. 
‘‘(2) REPORT
ELEMENTS.—Each report shall 
include—
‘‘(A) a description of efforts made to im-
plement the policies set forth in this section; 
‘‘(B) a description of the programs estab-
lished pursuant to this section; and 
‘‘(C) a detailed assessment of the impact 
of programs established pursuant to this sec-
tion, including—
‘‘(i) the effectiveness of such pro-
grams in reducing the spread of the HIV 
infection, particularly in women and girls, 
in reducing mother-to-child transmission of
the HIV infection, and in reducing mor-
tality rates from HIV/AIDS; and
‘‘(ii) the progress made toward im-
proving 
health 
care 
delivery 
systems 
(including the training of adequate num-
bers of staff) and infrastructure to ensure 
increased access to care and treatment. 
‘‘(f) FUNDING LIMITATION.—Of the funds made 
available to carry out this section in any fiscal year, not 
more than 7 percent may be used for the administrative 
expenses of the United States Agency for International 
Development in support of activities described in this sec-
tion. Such amount shall be in addition to other amounts 
otherwise available for such purposes. 
‘‘(g) DEFINITIONS.—In this section: 
‘‘(1) AIDS.—The term ‘AIDS’ means acquired 
immune deficiency syndrome. 
‘‘(2) HIV.—The term ‘HIV’ means the human 
immunodeficiency virus, the pathogen that causes 
AIDS. 
‘‘(3) 
HIV/AIDS.—The 
term 
‘HIV/AIDS’ 
means, with respect to an individual, an individual 
who is infected with HIV or living with AIDS.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds avail-
able under section 104(c) of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151b(c)) for such purpose 
or under any other provision of that Act, there are 
authorized to be appropriated to the President 
$550,000,000 
for 
the 
fiscal 
year 
2003 
and 
$900,000,000 for the fiscal year 2004 to carry out 
section 104A of the Foreign Assistance Act of 1961, 
as added by subsection (a). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
(3) ALLOCATION OF FUNDS.—
(A) RESEARCH ON MICROBICIDES.—Of the 
amounts authorized to be appropriated by para-
graph (1) for the fiscal years 2003 and 2004, 
$18,000,000 for the fiscal year 2003 and 
$24,000,000 for the fiscal year 2004 are au-
thorized to be available to carry out section 
104A(d)(1)(D) of the Foreign Assistance Act of 
1961 (as added by subsection (a)), relating to 
research on microbicides which prevent the 
spread of HIV/AIDS. 
(B) PHARMACEUTICALS.—Of the amounts 
authorized to be appropriated by paragraph (1)
for 
the 
fiscal 
years 
2003 
and 
2004, 
$50,000,000 for the fiscal year 2003 and 
$120,000,000 for the fiscal year 2004 are au-
thorized to be available to carry out section 
104A(d)(4) of the Foreign Assistance Act of 
1961 (as added by subsection (a)), relating to 
the procurement and distribution of HIV/AIDS 
pharmaceuticals. 
(4) TRANSFER OF PRIOR YEAR FUNDS.—Unob-
ligated balances of funds made available for the fis-
cal year 2001 or the fiscal year 2002 under section 
104(c)(6) of the Foreign Assistance Act of 1961 (22 
U.S.C. 2151b(c)(6) (as in effect immediately before 
the date of enactment of this Act) shall be trans-
ferred to, merged with, and made available for the 
same purposes as funds made available for fiscal 
year 2003 under paragraph (1). 
SEC. 302. ASSISTANCE TO COMBAT TUBERCULOSIS. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.), as amended by sec-
tion 301 of this Act, is further amended by inserting after 
section 104A the following new section:
‘‘SEC. 104B. ASSISTANCE TO COMBAT TUBERCULOSIS. 
‘‘(a) FINDINGS.—Congress makes the following find-
ings: 
‘‘(1) Congress recognizes the growing inter-
national problem of tuberculosis and the impact its 
continued existence has on those countries that had 
previously largely controlled the disease. 
‘‘(2) Congress further recognizes that the 
means exist to control and treat tuberculosis 
through expanded use of the DOTS (Directly Ob-
served Treatment Short-course) treatment strategy 
and adequate investment in newly created mecha-
nisms to increase access to treatment, including the 
Global Tuberculosis Drug Facility established in 
2001 pursuant to the Amsterdam Declaration to 
Stop TB. 
‘‘(b) POLICY.—It is a major objective of the foreign 
assistance program of the United States to control tuber-
culosis, including the detection of at least 70 percent of 
the cases of infectious tuberculosis, and the cure of at 
least 85 percent of the cases detected, not later than De-
cember 31, 2005, in those countries classified by the 
World Health Organization as among the highest tuber-
culosis burden, and not later than December 31, 2010, 
in all countries in which the United States Agency for
International Development has established development 
programs. 
‘‘(c) AUTHORIZATION.—To carry out this section and 
consistent with section 104(c), the President is authorized 
to furnish assistance, on such terms and conditions as the 
President may determine, for the prevention, treatment, 
control, and elimination of tuberculosis. 
‘‘(d) COORDINATION.—In carrying out this section, 
the President shall coordinate with the World Health Or-
ganization, the Global Fund to Fight AIDS, Tuberculosis, 
and Malaria, the Department of Health and Human Serv-
ices (including the Centers for Disease Control and Pre-
vention and the National Institutes of Health), and other 
organizations with respect to the development and imple-
mentation of a comprehensive tuberculosis control pro-
gram. 
‘‘(e) ANNUAL REPORT.—Not later than January 31 
of each year, the President shall submit a report to the 
Committee on Foreign Relations of the Senate and the 
Committee on International Relations of the House of 
Representatives specifying the increases in the number of 
people treated and the increases in number of tuberculosis 
patients cured through each program, project, or activity 
receiving United States foreign assistance for tuberculosis 
control purposes.
‘‘(f) PRIORITY TO DOTS COVERAGE.—In furnishing 
assistance under subsection (c), the President shall give 
priority to activities that increase directly observed treat-
ment shortcourse (DOTS) coverage, including funding for
the Global Tuberculosis Drug Facility and the Stop Tu-
berculosis Partnership. 
‘‘(g) DEFINITIONS.—In this section: 
‘‘(1) DOTS.—The term ‘DOTS’ or ‘Directly 
Observed Treatment Short-course’ means the World 
Health 
Organization-recommended 
strategy 
for 
treating tuberculosis. 
‘‘(2) GLOBAL
TUBERCULOSIS
DRUG
FACIL-
ITY.—The term ‘Global Tuberculosis Drug Facility 
(GDF)’ means the new initiative of the Stop Tuber-
culosis Partnership to increase access to high-quality 
tuberculosis drugs to facilitate DOTS expansion. 
‘‘(3) STOP TUBERCULOSIS PARTNERSHIP.—The 
term ‘Stop Tuberculosis Partnership’ means the 
partnership of the World Health Organization, do-
nors including the United States, high tuberculosis 
burden countries, multilateral agencies, and non-
governmental and technical agencies committed to 
short- and long-term measures required to control 
and eventually eliminate tuberculosis as a public 
health problem in the world.’’.
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds avail-
able under section 104(c) of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151b(c)) for such purpose 
or under any other provision of that Act, there are 
authorized to be appropriated to the President 
$85,000,000 
for 
the 
fiscal 
year 
2003 
and 
$200,000,000 for the fiscal year 2004 to carry out 
section 104B of the Foreign Assistance Act of 1961, 
as added by subsection (a). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
(3) TRANSFER OF PRIOR YEAR FUNDS.—Unob-
ligated balances of funds made available for the fis-
cal year 2001 or the fiscal year 2002 under section 
104(c)(7) of the Foreign Assistance Act of 1961 (22 
U.S.C. 2151b(c)(7) (as in effect immediately before 
the date of enactment of this Act) shall be trans-
ferred to, merged with, and made available for the 
same purposes as funds made available for fiscal 
year 2003 under paragraph (1). 
SEC. 303. ASSISTANCE TO COMBAT MALARIA. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance
Act of 1961 (22 U.S.C. 2151 et seq.), as amended by sec-
tions 301 and 302 of this Act, is further amended by in-
serting after section 104B the following new section: 
‘‘SEC. 104C. ASSISTANCE TO COMBAT MALARIA. 
‘‘(a) FINDING.—Congress finds that malaria kills 
more people annually than any other communicable dis-
ease except tuberculosis, that more than 90 percent of all 
malaria cases are in sub-Saharan Africa, and that children 
and women are particularly at risk. Congress recognizes 
that there are cost-effective tools to decrease the spread 
of malaria and that malaria is a curable disease if prompt-
ly diagnosed and adequately treated. 
‘‘(b) POLICY.—It is a major objective of the foreign 
assistance program of the United States to provide assist-
ance for the prevention, control, and cure of malaria. 
‘‘(c) AUTHORIZATION.—To carry out this section and 
consistent with section 104(c), the President is authorized 
to furnish assistance, on such terms and conditions as the 
President may determine, for the prevention, treatment, 
control, and elimination of malaria. 
‘‘(d) COORDINATION.—In carrying out this section, 
the President shall coordinate with the World Health Or-
ganization, the Global Fund to Fight AIDS, Tuberculosis, 
and Malaria, the Department of Health and Human Serv-
ices (the Centers for Disease Control and Prevention and
the National Institutes of Health), and other organiza-
tions with respect to the development and implementation 
of a comprehensive malaria control program. 
‘‘(e) ANNUAL REPORT.—Not later than January 31 
of each year, the President shall submit a report to the 
Committee on Foreign Relations of the Senate and the 
Committee on International Relations of the House of 
Representatives specifying the increases in the number of 
people treated and the increases in number of malaria pa-
tients cured through each program, project, or activity re-
ceiving United States foreign assistance for malaria con-
trol purposes.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds avail-
able under section 104(c) of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151b(c)) for such purpose 
or under any other provision of that Act, there are 
authorized to be appropriated to the President 
$70,000,000 
for 
the 
fiscal 
year 
2003 
and 
$80,000,000 for the fiscal year 2004 to carry out 
section 104C of the Foreign Assistance Act of 1961, 
as added by subsection (a). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended.
(3) TRANSFER OF PRIOR YEAR FUNDS.—Unob-
ligated balances of funds made available for the fis-
cal year 2001 or the fiscal year 2002 under section 
104(c) of the Foreign Assistance Act of 1961 (22 
U.S.C. 2151b(c) (as in effect immediately before the 
date of enactment of this Act) and made available 
for the control of malaria shall be transferred to, 
merged with, and made available for the same pur-
poses as funds made available for fiscal year 2003 
under paragraph (1). 
(c) CONFORMING AMENDMENT.—Section 104(c) of 
the Foreign Assistance Act of 1961 (22 U.S.C. 2151b(c)), 
as amended by section 301 of this Act, is further amended 
by adding after paragraph (3) the following: 
‘‘(4) RELATIONSHIP TO OTHER LAWS.—Assist-
ance made available under this subsection and sec-
tions 104A, 104B, and 104C, and assistance made 
available under chapter 4 of part II to carry out the 
purposes of this subsection and such other sections 
of this Act, may be made available in accordance 
with this subsection and such other provisions of 
this Act notwithstanding any other provision of 
law.’’.
SEC. 304. PILOT PROGRAM FOR THE PLACEMENT OF 
HEALTH CARE PROFESSIONALS IN OVERSEAS 
AREAS SEVERELY AFFECTED BY HIV/AIDS, 
TUBERCULOSIS, AND MALARIA. 
(a) IN GENERAL.—The President shall establish a 
program to demonstrate the feasibility of facilitating the 
service of American health care professionals in sub-Saha-
ran Africa and other parts of the world severely affected 
by HIV/AIDS, tuberculosis, and malaria. 
(b) REQUIREMENTS.—Participants in the program 
shall—
(1) provide basic health care services for those 
infected and affected by HIV/AIDS, tuberculosis, 
and malaria in the area in which they are serving; 
(2) provide on-the-job training to medical and 
other personnel in the area in which they are serving 
to strengthen the basic health care system of the af-
fected countries; 
(3) provide health care educational training for 
residents of the area in which they are serving; 
(4) serve for a period of up to two years; and 
(5) meet the eligibility requirements in sub-
section (d). 
(c) ELIGIBILITY REQUIREMENTS.—To be eligible to 
participate in the program, a candidate shall—
(1) be a national of the United States who is 
a trained health care professional and who meets the 
educational and licensure requirements necessary to 
be such a professional such as a physician, nurse, 
nurse practitioner, pharmacist, or other individual 
determined to be appropriate by the President; or 
(2) a retired commissioned officer of the Public 
Health Service Corps. 
(d) RECRUITMENT.—The President shall ensure that 
information on the program is widely distributed, includ-
ing the distribution of information to schools for health 
professionals, hospitals, clinics, and nongovernmental or-
ganizations working in the areas of international health 
and aid. 
(e) PLACEMENT OF PARTICIPANTS.—To the max-
imum extent practicable, participants in the program shall 
serve in the poorest areas of the affected countries, where 
health care needs are likely to be the greatest. The deci-
sion on the placement of a participant should be made in 
consultation with relevant officials of the affected country 
at both the national and local level as well as with local 
community leaders and organizations. 
(f) EXTENDED PERIOD OF SERVICE.—The President 
may extend the period of service of a participant by an 
additional period of 6 to 12 months.
(g) INCENTIVES.—The President may offer such in-
centives as the President determines to be necessary to 
encourage individuals to participate in the program, such 
as partial payment of principal, interest, and related ex-
penses on government and commercial loans for edu-
cational expenses relating to professional health training 
and, where possible, deferment of repayments on such 
loans, the provision of retirement benefits that would oth-
erwise be jeopardized by participation in the program, and 
other incentives. 
(h) REPORT.—Not later than 18 months after the 
date of enactment of this Act, the President shall submit 
a report to the designated congressional committees on 
steps taken to establish the program, including—
(1) the process of recruitment, including the 
venues for recruitment, the number of candidates re-
cruited, the incentives offered, if any, and the cost 
of those incentives; 
(2) the process, including the criteria used, for 
the selection of participants; 
(3) the number of participants placed, the coun-
tries in which they were placed, and why those coun-
tries were selected; and 
(4) the potential for expansion of the program. 
(i) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to amounts oth-
erwise available for such purpose, there is authorized 
to be appropriated to the President $20,000,000 for 
the fiscal year 2004 to carry out the program. 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
SEC. 305. REPORT ON TREATMENT ACTIVITIES BY REL-
EVANT EXECUTIVE BRANCH AGENCIES. 
(a) IN GENERAL.—Not later than 15 months after 
the date of enactment of this Act, the President shall sub-
mit to designated congressional committees a report on 
the programs and activities of the United States Agency 
for International Development, the Centers for Disease 
Control and Prevention, and other relevant Executive 
branch agencies that are directed to the treatment of indi-
viduals in foreign countries infected with HIV or living 
with AIDS. 
(b) REPORT ELEMENTS.—The report shall include—
(1) a description of the activities of relevant 
Executive branch agencies with respect to—
(A) the treatment of opportunistic infec-
tions; 
(B) the use of antiretrovirals;
(C) the status of research into successful 
treatment protocols for individuals in the devel-
oping world; and 
(D) technical assistance and training of 
local health care workers (in countries affected 
by the pandemic) to administer antiretrovirals, 
manage side effects, and monitor patients’ viral 
loads and immune status; 
(2) information on existing pilot projects, in-
cluding a discussion of why a given population was 
selected, the number of people treated, the cost of 
treatment, the mechanisms established to ensure 
that treatment is being administered effectively and 
safely, and plans for scaling up pilot projects 
(including projected timelines and required re-
sources); and 
(3) an explanation of how those activities relate 
to efforts to prevent the transmission of the HIV in-
fection. 
Subtitle B—Assistance for Children 
and Families 
SEC. 311. FINDINGS. 
Congress makes the following findings: 
(1) Approximately 2,000 children around the 
world are infected each day with HIV through moth-
er-to-child transmission. Transmission can occur 
during pregnancy, labor, and delivery or through 
breast feeding. Over ninety percent of these cases 
are in developing nations with little or no access to 
public health facilities. 
(2) Mother-to-child transmission is largely pre-
ventable with the proper application of pharma-
ceuticals, therapies, and other public health interven-
tions. 
(3) The drug nevirapine, reduces mother-to-
child transmission by nearly 50 percent. Universal 
availability of this drug could prevent up to 400,000 
infections per year and dramatically reduce the num-
ber of AIDS-related deaths. 
(4) At the United Nations Special Session on 
HIV/AIDS in June 2001, the United States com-
mitted to the specific goals with respect to the pre-
vention of mother-to-child transmission, including 
the goals of reducing the proportion of infants in-
fected with HIV by 20 percent by the year 2005 and 
by 50 percent by the year 2010, as specified in the 
Declaration of Commitment on HIV/AIDS adopted 
by the United Nations General Assembly at the Spe-
cial Session.
(5) Several United States Government agencies 
including the United States Agency for International 
Development and the Centers for Disease Control 
are already supporting programs to prevent mother-
to-child transmission in resource-poor nations and 
have the capacity to expand these programs rapidly 
by working closely with foreign governments and 
nongovernmental organizations. 
(6) Efforts to prevent mother-to-child trans-
mission can provide the basis for a broader response 
that includes care and treatment of mothers, fa-
thers, and other family members that are infected 
with HIV or living with AIDS. 
(7) HIV/AIDS has devastated the lives of 
countless children and families across the globe. 
Since the epidemic began, an estimated 13,200,000 
children under the age of 15 have been orphaned by 
AIDS, that is they have lost their mother or both 
parents to the disease. The Joint United Nations 
Program on HIV/AIDS (UNAIDS) estimates that 
this number will double by the year 2010. 
(8) HIV/AIDS also targets young people be-
tween the ages of 15 to 24, many of whom carry the 
burden of caring for family members living with 
HIV/AIDS. An estimated 10,300,000 young people
are now living with HIV/AIDS. One-half of all new 
infections are occurring among this age group. 
SEC. 312. POLICY AND REQUIREMENTS. 
(a) POLICY.—The United States Government’s re-
sponse to the global HIV/AIDS pandemic should place 
high priority on the prevention of mother-to-child trans-
mission, the care and treatment of family members and 
caregivers, and the care of children orphaned by AIDS. 
To the maximum extent possible, the United States Gov-
ernment should seek to leverage its funds by seeking 
matching contributions from the private sector, other na-
tional governments, and international organizations. 
(b) REQUIREMENTS.—The 5-year United States Gov-
ernment strategy required by section 101 of this Act 
shall—
(1) provide for meeting or exceeding the goal 
set by the United Nations General Assembly Dec-
laration of Commitment on HIV/AIDS to reduce the 
rate of mother-to-child transmission of HIV by 20 
percent by 2005 and by 50 percent by 2010; 
(2) include programs to make available testing 
and treatment to HIV-positive women and their 
family members, including drug treatment and 
therapies to prevent mother-to-child transmission; 
and
(3) expand programs designed to care for chil-
dren orphaned by AIDS. 
SEC. 313. ANNUAL REPORTS ON PREVENTION OF MOTHER-
TO-CHILD TRANSMISSION OF THE HIV INFEC-
TION. 
(a) IN GENERAL.—Beginning 270 days after the date 
of enactment of this Act, and annually thereafter for the 
ensuing eight years, the President shall submit to des-
ignated congressional committees a report on the activities 
of relevant Executive branch agencies during the reporting 
period to assist in the prevention of mother-to-child trans-
mission of the HIV infection. 
(b) REPORT ELEMENTS.—Each report shall in-
clude—
(1) a statement of whether or not all relevant 
Executive branch agencies have adopted the targets 
set by the United Nations General Assembly at the 
Special Session for HIV/AIDS, held June 25 to 27, 
2001, with respect to mother-to-child transmission 
of the HIV infection; 
(2) a description of efforts made by the United 
States Agency for International Development and 
the Centers for Disease Control and Prevention to 
expand those activities, including—
(A) information on the number of sites 
supported for the prevention of mother-to-child 
transmission of the HIV infection; 
(B) the specific activities supported; 
(C) the number of women tested and coun-
seled; and 
(D) the number of women receiving pre-
ventative drug therapies; 
(3) a statement of the percentage of funds ex-
pended out of the budget of each relevant Executive 
branch agency for activities to prevent mother-to-
child transmission of the HIV infection and, in the 
case of United States Agency for International De-
velopment, whether or not its expenditures on bilat-
eral assistance have met the 8.3 percent target in 
section 104(c)(6)(D) of the Foreign Assistance Act 
of 1961 (22 U.S.C. 2151b(c)(6)(D)), as in effect im-
mediately before the date of enactment of this Act, 
with respect to strategies to prevent mother-to-child 
transmission of the HIV infection; 
(4) a discussion of the extent to which the pro-
grams of the relevant Executive branch agencies are 
meeting targets set by the United Nations General 
Assembly; and
(5) a description of efforts made by the Centers 
for Disease Control and Prevention and the United 
States Agency for International Development to ex-
pand care and treatment services for families at es-
tablished sites for the prevention of mother-to-child 
transmission of HIV infection. 
(c) REPORTING PERIOD DEFINED.—In this section, 
the term ‘‘reporting period’’ means, in the case of the ini-
tial report, the period since the date of enactment of this 
Act and, in the case of any subsequent report, the period 
since the date of submission of the most recent report. 
SEC. 314. PILOT PROGRAM OF ASSISTANCE FOR CHILDREN 
AND FAMILIES AFFECTED BY HIV/AIDS. 
(a) IN GENERAL.—The President, acting through the 
United States Agency for International Development, shall 
establish a program of assistance that would demonstrate 
the feasibility of the provision of care and treatment to 
orphans and other children and young people affected by 
HIV/AIDS in foreign countries. 
(b) 
PROGRAM
REQUIREMENTS.—The 
program 
shall—
(1) build upon and be integrated into programs 
administered as of the date of enactment of this Act 
by the United States Agency for International De-
velopment for children affected by HIV/AIDS;
(2) work in conjunction with indigenous com-
munity-based programs and activities, particularly 
those that offer proven services for children; 
(3) reduce the stigma of HIV/AIDS to encour-
age vulnerable children infected with HIV or living 
with AIDS and their family members and caregivers 
to avail themselves of voluntary counseling and test-
ing, and related programs, including treatments; 
(4) provide, in conjunction with other relevant 
Executive branch agencies, the range of services for 
the care and treatment, including the provision of 
antiretrovirals and other necessary pharmaceuticals, 
of children, parents, and caregivers infected with 
HIV or living with AIDS; 
(5) provide nutritional support and food secu-
rity, and the improvement of overall family health; 
(6) work with parents, caregivers, and commu-
nity-based organizations to provide children with 
educational opportunities; and 
(7) provide appropriate counseling and legal as-
sistance for the appointment of guardians and the 
handling of other issues relating to the protection of 
children. 
(c) REPORT.—Not later than 18 months after the 
date of enactment of this Act, the President, acting
through the United States Agency for International Devel-
opment, shall submit a report on the implementation of 
this section to the appropriate congressional committees. 
The report shall include a plan for scaling up the program 
over the following year. 
(d) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to amounts oth-
erwise available for such purpose, there is authorized 
to be appropriated to the President $30,000,000 for 
the fiscal year 2004 to carry out the program. 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
TITLE IV—BUSINESS 
PRINCIPLES 
SEC. 401. PRINCIPLES FOR UNITED STATES FIRMS OPER-
ATING IN COUNTRIES AFFECTED BY THE HIV/
AIDS PANDEMIC. 
(a) FINDINGS.—Congress finds that the global 
spread of HIV/AIDS presents not only a health crisis but 
also a crisis in the workplace that affects—
(1) the productivity, earning power, and lon-
gevity of individual workers; 
(2) the productivity, competitiveness, and finan-
cial solvency of individual businesses; and
(3) the economic productivity and development 
of individual communities and the United States as 
a whole. 
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that United States firms operating in countries af-
fected by the HIV/AIDS pandemic can make significant 
contributions to the United States effort to respond to this 
pandemic through the voluntary adoption of the principles 
and practices described in subsection (c). 
(c) PRINCIPLES
AND PRACTICES.—The principles 
and practices referred to in subsection (b) are the fol-
lowing: 
(1) With respect to employment and health poli-
cies and practices, the treatment of HIV/AIDS in 
the same manner as any other illness. 
(2) The promotion of policies and practices that 
eliminate discrimination and stigmatization against 
employees on the basis of real or perceived HIV/
AIDS status, including—
(A) assessing employees on merit and abil-
ity to perform; 
(B) not subjecting employees to personal 
discrimination or abuse; and 
(C) imposing disciplinary measures where 
discrimination occurs.